The potential reassessment of cannabinoids, particularly at the federal level, is generating considerable excitement within the market. A shift away from Schedule I status, often viewed as outdated and hindering https://bookmarkpagerank.com/story20771446/cannabinoid-rescheduling-a-growth-catalyst